EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische Studie

Effects of bempedoic acid on CRP, IL-6, fibrinogen and lipoprotein(a) in patients with residual inflammatory risk: A secondary analysis of the CLEAR harmony trial

Paul M Ridker, Lei Lei, Kausik K Ray, Christie M Ballantyne, Gary Bradwin, Nader Rifai

Journal of Clinical Lipidology · 2023

DOI: 10.1016/j.jacl.2023.02.002 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of Clinical Lipidology, 2023. Verfasst von Paul M Ridker und 5 weiteren Autor:innen. Beteiligte Einrichtung: Center for Cardiovascular Disease Prevention, Divisions of Preventive Medicine and Cardiovascular Disease, Brigham and Women's Hospital, Harvard Medi…. Hauptthemen laut MEDLINE: Hydroxymethylglutaryl-CoA Reductase Inhibitors. Die Arbeit wurde bisher 68-mal zitiert (Crossref) und nennt 18 Literaturangaben. Gefördert von: Esperion Therapeutics.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

While bempedoic acid (BA), an inhibitor of ATP citrate lyase, lowers high-sensitivity C-reactive protein (hsCRP) and low-density lipoprotein cholesterol (LDL-C), the mechanisms underlying the potential anti-inflammatory effects of BA are uncertain, as are effects of this agent on lipoprotein(a). To address these issues, we conducted a secondary biomarker analysis of the randomized placebo-controlled multi-center CLEAR Harmony trial which included 817 patients with known atherosclerotic disease and/or heterozygous familial hypercholesterolemia who were taking maximally tolerated statin therapy and had residual inflammatory risk, defined as a baseline hsCRP ≥2 mg/L. Participants were randomly allocated in a 2:1 ratio to oral BA 180 mg once daily or matching placebo. Placebo-corrected median percent changes (95% CI) from baseline to 12 weeks associated with BA were -21.1% (-23.7 to -18.5) for LDL-C; -14.3% (-16.8 to -11.9) for non-high-density lipoprotein cholesterol; -12.8% (-14.8 to -10.8) for total cholesterol; -8.3% (-10.1 to -6.6) for high-density lipoprotein cholesterol (HDL-C); -13.1% (-15.5 to -10.6) for apolipoprotein B; 8.0% (3.7 to 12.5) for triglycerides; -26.5% (-34.8 to -18.4) for hsCRP; 2.1% (-2.0 to 6.4) for fibrinogen, -3.7% (-11.5, 4.3) for interleukin-6; and 2.4% (0.0 to 4.8) for lipoprotein(a). There was no correlation between BA associated lipid changes and BA associated change in hsCRP (all r

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hydroxymethylglutaryl-CoA Reductase InhibitorsHumansCholesterol, LDLInterleukin-6C-Reactive ProteinFibrinogenLipoprotein(a)Treatment OutcomeCholesterolDouble-Blind MethodDicarboxylic AcidsFatty Acids

Stichwörter der Autor:innen

Bempedoic acidInflammationLipidsLipoprotein(a)Prevention

Substanzen

Hydroxymethylglutaryl-CoA Reductase InhibitorsCholesterol, LDLInterleukin-6C-Reactive ProteinFibrinogenLipoprotein(a)Cholesterol8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acidDicarboxylic AcidsFatty Acids

Autor:innen und Institutionen

  • Center for Cardiovascular Disease Prevention, Divisions of Preventive Medicine and Cardiovascular Disease, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, United States. Electronic address: pridker@bwh…
  • United Kingdom Esperion Therapeutics, Inc., Ann Arbor, Michigan, United States.
  • Department of Primary Care and Public Health Imperial College London, London, United Kingdom.
  • Department of Medicine Baylor College of Medicine, Houston, Texas, United States.
  • Children's Hospital Medical Center, Boston, Massachusetts, United States.

Förderung

  • Esperion Therapeutics

Zitieren

APA

Ridker, P. M., Lei, L., Ray, K. K., Ballantyne, C. M., Bradwin, G., & Rifai, N. (2023). Effects of bempedoic acid on CRP, IL-6, fibrinogen and lipoprotein(a) in patients with residual inflammatory risk: A secondary analysis of the CLEAR harmony trial. Journal of Clinical Lipidology. https://doi.org/10.1016/j.jacl.2023.02.002

Vancouver

Ridker PM, Lei L, Ray KK, Ballantyne CM, Bradwin G, Rifai N. Effects of bempedoic acid on CRP, IL-6, fibrinogen and lipoprotein(a) in patients with residual inflammatory risk: A secondary analysis of the CLEAR harmony trial. Journal of Clinical Lipidology. 2023. doi:10.1016/j.jacl.2023.02.002

BibTeX
@article{Ridker2023,
  author = {Ridker, Paul M and Lei, Lei and Ray, Kausik K and Ballantyne, Christie M and Bradwin, Gary and Rifai, Nader},
  title = {Effects of bempedoic acid on CRP, IL-6, fibrinogen and lipoprotein(a) in patients with residual inflammatory risk: A secondary analysis of the CLEAR harmony trial},
  journal = {Journal of Clinical Lipidology},
  year = {2023},
  doi = {10.1016/j.jacl.2023.02.002}
}
Kostenlos starten →